Leukemia therapy with imatinib during pregnancy may cause infant abnormalities

Mar 05, 2008

While doctors already face many challenges in treating patients with cancer, treating pregnant women with the disease, in particular, can be quite difficult as studies suggest that certain therapies can harm developing fetuses. According to the results of a study prepublished today online in Blood, the official journal of the American Society of Hematology, expectant women treated with imatinib, a commonly used therapy for chronic myeloid leukemia (CML), may be at moderate risk of developing fetal abnormalities.

Imatinib was introduced for the treatment of CML in 1998 and has become a primary therapy for most patients, turning the previously fatal disease into a mostly chronic condition in the last decade. The drug's label warns that women of child-bearing age should avoid pregnancy while taking the drug based on earlier studies that suggested it may penetrate the placenta and cause damage to developing cells.

The retrospective study reviewed records of 180 cases of CML treatment during pregnancy reported to Novartis, the Hammersmith Hospital in London, or The University of Texas M. D. Anderson Cancer Center to determine the real risks of imatinib therapy. Specific outcomes data were available for 125 of the cases, as 55 cases had incomplete pregnancy-related data.

Half of the pregnancies resulted in the birth of normal live infants (n=63). Thirty-five women underwent elective terminations, three following the identification of fetal abnormalities. At least 18 pregnancies resulted in miscarriage. The remainder of the births resulted in infants with congenital abnormalities (n=9, one still birth). In total, 12 pregnancies resulted in infants with fetal abnormalities (9.6 percent) and of those, there were eight live births, one still birth and three terminations (mentioned above). Some of the abnormalities in the infants were similar, including exomphalos (umbilical hernia), renal agenesis (undeveloped kidney), and hemivertebrae (underdeveloped spine). The stillborn child suffered from meningocoele (cerebral hernia).

The study showed that a significant proportion of pregnancies exposed to imatinib result in a normal outcome and a healthy infant. The miscarriage rate in the study was 14.4 percent, which is within the expected range for the general population. However, the fact that some of the abnormalities seen in the 12 infants were similar to results found in early animal studies with imatinib suggests the possibility of an imatinib-induced effect.

"Our study suggests that a concern about conceiving a child while taking imatinib is justified and that patients should be advised to avoid conception while on treatment," said Dr. Seonaid Pye, of the Department of Hematology, Imperial College of London and lead author of the study. "In those patients who do become pregnant, balancing the risk of the fetus from taking therapy to the risk of the mother from interrupting therapy will be an individual decision."

The majority of women in the study were being treated for CML at the time of conception; just four cases were exposed after the first trimester. The dose and the exact duration of imatinib therapy are unknown for most cases, with insufficient information to assess a dose-related relationship. There were no reports of maternal exposure to alcohol, drugs, or tobacco addiction during pregnancy, and none of the mothers had received other high-dose chemotherapy prior to their pregnancies.

"The risks and benefits to an expectant woman fighting cancer and her fetus are challenging and must be evaluated on an individual basis with careful counseling," said Dr. Pye. "Ultimately, the treatment of CML during pregnancy clearly remains a considerable clinical challenge."

Source: American Society of Hematology

Explore further: UN Ebola victim leaves France after recovery

add to favorites email to friend print save as pdf

Related Stories

New lab test could identify imatinib resistance

Jul 29, 2010

Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML).

Combination therapy targets stubborn leukemia stem cells

May 17, 2010

New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia. The study, published by Cell Press in the May issue of the journal Cancer Cell, reports that the ne ...

Recommended for you

US looking past Ebola to prepare for next outbreak

6 hours ago

The next Ebola or the next SARS. Maybe even the next HIV. Even before the Ebola epidemic in West Africa is brought under control, U.S. public health officials are girding for the next health disaster.

Can robots help stop the Ebola outbreak?

14 hours ago

The US military has enlisted a new germ-killing weapon in the fight against Ebola—a four-wheeled robot that can disinfect a room in minutes with pulses of ultraviolet light.

New bird flu case in Germany

14 hours ago

A worrying new strain of bird flu has been observed for the first time in a wild bird in northern Germany, the agriculture ministry said Saturday.

Mali announces new Ebola case

Nov 22, 2014

Mali announced Saturday a new case of Ebola in a man who is fighting for his life in an intensive care unit in the capital Bamako.

Plague outbreak kills 40 in Madagascar: WHO

Nov 22, 2014

An outbreak of plague has killed 40 people in Madagascar, the World Health Organization said, warning that the disease could spread rapidly in the country's densely populated capital Antananarivo.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.